PDCD1 and intrahepatic cholangiocarcinoma: To our knowledge, this is the first, largest sample size and multicenter study to investigate PD-1 inhibitors plus lenvatinib with Gemox chemotherapy as the first-line treatment option for advanced ICC in a real-world study.